Skip to Content

Gallium Citrate Ga 67 use while Breastfeeding

Drugs containing Gallium Citrate Ga 67: Mallinckrodt Gallium (67Ga) Citrate, ARI Gallium (Ga-67) Citrate, Bristol-Myers Squibb Gallium (67Ga) Citrate

Gallium Citrate Ga 67 Levels and Effects while Breastfeeding

Summary of Use during Lactation

Information in this record refers to the use of Ga 67 citrate as a diagnostic agent. The United States Nuclear Regulatory Commission states that breastfeeding should be interrupted temporarily after administration of Ga 67 citrate to a nursing mother. The duration of breastfeeding interruption depends on the dose administered (see table).[1] The International Commission on Radiological Protection recommends discontinuation of breastfeeding for more than 3 weeks after Ga 67 citrate.[2] Those receiving the higher doses might have to permanently discontinue breastfeeding this infant.[3][4] After doses greater than 200 MBq, consideration of temporarily limiting close contact between the mother and infant.[5]

During the period of interruption, the breasts should be emptied regularly and completely. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[3][5][6] The milk that is pumped by the mother during the time of breastfeeding interruption can either be discarded or[3][6] stored frozen and given to the infant after 10 physical half-lives, or about 33 days, have elapsed.

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[4] Mothers who receive a dose less than 190 MBq for an inflammation scan need not refrain from close contact with their infants.[7]

Dose Duration of Interruption[1]
150 MBq (4 mCi) 1 month
50 MBq (1.3 mCi) 2 weeks
7 MBq (0.2 mCi) 1 week

Drug Levels

Ga 67 decays by electron capture with principal photon energies of 93.3, 184.6 and 300.2 keV, and a physical half-life of 3.261 days.[1] The effective half-life of gallium 67 citrate ranges from 40 to 68 hours.[3][4]

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.


1. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2.

2. Mattsson S, Johansson L, Leide Svegborn S et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP. 2015;44 (2 Suppl):319-21. PMID: 26069086

3. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. PMID: 2645546

4. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PMID: 10809203

5. Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2006;25-7.

6. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc. 1995:1380-1.

7. Mountford PJ, O'Doherty MJ. Exposure of critical groups to nuclear medicine patients. Appl Radiat Isot. 1999;50:89-111. PMID: 10028630

Gallium Citrate Ga 67 Identification

Substance Name

Gallium Citrate Ga 67

CAS Registry Number


Drug Class


Gallium Radioisotopes

Administrative Information

LactMed Record Number


Last Revision Date



Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.